Soleus Capital Management’s Immunic IMUX Stock Holding History

Soleus Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.92M	Hold	450,000	–	–	0.24%	69
2026 Q1	$5M	Buy	+450,000	New	+$4.03M	0.2%	65
2025 Q4	–	Sell	-158,001	Closed	-$1.39M	–	108
2025 Q3	$1.39M	Sell	158,001 -571,300	-78%	-$5.04M	0.07%	77
2025 Q2	$5.09M	Hold	729,301	–	–	0.34%	53
2025 Q1	$7.95M	Hold	729,301	–	–	0.57%	43
2024 Q4	$7.29M	Hold	729,301	–	–	0.46%	48
2024 Q3	$12M	Hold	729,301	–	–	0.93%	36
2024 Q2	$8.1M	Hold	729,301	–	–	0.71%	45
2024 Q1	$9.63M	Buy	729,301 +699,301	+2,331%	+$9.09M	0.71%	41
2023 Q4	$450K	Hold	30,000	–	–	0.05%	68
2023 Q3	$441K	Hold	30,000	–	–	0.04%	90
2023 Q2	$753K	Hold	30,000	–	–	0.08%	89
2023 Q1	$447K	Buy	+30,000	New	+$557K	0.05%	75
2022 Q4	–	Sell	-24,000	Closed	-$758K	–	79
2022 Q3	$758K	Hold	24,000	–	–	0.1%	72
2022 Q2	$833K	Hold	24,000	–	–	0.13%	70
2022 Q1	$2.71M	Buy	24,000 +6,500	+37%	+$752K	0.35%	50
2021 Q4	$1.68M	Buy	+17,500	New	+$1.58M	0.17%	55

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Soleus Capital Management's IMUX Position: Q2 2026 in Review

Soleus Capital Management held its Immunic (IMUX) position steady in Q2 2026 at 450,000 shares worth $6.92M. The position accounts for 0.24% of the portfolio, ranked #69.

Soleus Capital Management first reported a position in IMUX in Q4 2021 and has held it in 17 quarters since. The position peaked at $12M in Q3 2024. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Soleus Capital Management held 450,000 shares of Immunic worth $6.92M as of Q2 2026.
Soleus Capital Management left its Immunic share count unchanged in Q2 2026.
Immunic made up 0.24% of Soleus Capital Management's portfolio in Q2 2026, its #69 holding.
Soleus Capital Management first reported a position in Immunic in Q4 2021 and has held it in 17 quarters since.
Soleus Capital Management's Immunic position peaked at $12M in Q3 2024.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.